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Abstract 
Background 
There is tremendous potential for genome sequencing to improve clinical diagnosis and care 
once it becomes routinely accessible, but this will require formalizing research methods into 
clinical best practices in the areas of sequence data generation, analysis, interpretation and 
reporting. The CLARITY Challenge was designed to spur convergence in methods for 
diagnosing genetic disease starting from clinical case history and genome sequencing data. 
DNA samples were obtained from three families with heritable genetic disorders and 
genomic sequence data was donated by sequencing platform vendors. The challenge was to 
analyze and interpret these data with the goals of identifying disease causing variants and 
reporting the findings in a clinically useful format. Participating contestant groups were 
solicited broadly, and an independent panel of judges evaluated their performance. 
Results 
A total of 30 international groups were engaged. The entries reveal a general convergence of 
practices on most elements of the analysis and interpretation process. However, even given 
this commonality of approach, only two groups identified the consensus candidate variants in 
all disease cases, demonstrating a need for consistent fine-tuning of the generally accepted 
methods. There was greater diversity of the final clinical report content and in the patient 
consenting process, demonstrating that these areas require additional exploration and 
standardization. 
Conclusions 
The CLARITY Challenge provides a comprehensive assessment of current practices for 
using genome sequencing to diagnose and report genetic diseases. There is remarkable 
convergence in bioinformatic techniques, but medical interpretation and reporting are areas 
that require further development by many groups. 
Background 
The transition of genomics from research into clinical practice has begun, predicated on 
rapidly improving technology, data analysis methods, and more recently and importantly, 
standardization [1,2]. Methods and tools for genomic diagnostics have quickly evolved to 
encompass all of the processes from consenting, through data generation and analysis, to 
interpretation, prioritization, and revisable reporting [3]. Nonetheless, there is not currently a 
widely accepted set of published standards to enable the consistent and widespread use of 
genomics in the practice of medicine. 
There have been a growing number of publicized successes in the application of genomic 
sequencing and interpretations for children with rare diseases of unknown etiology and 
patients with refractory cancers [4-11]. This has led to a growing expectation that clinical 
whole exome or genome sequencing services will soon be standard practice for a much larger 
population of patients. Unlike other data-intensive diagnostic modalities such as MRI’s there 
are no standards for the use of computational tools to analyze the outputs of different next-
generation sequencing technologies for patient care [12]. There is a large methodological 
armamentarium for assembling genomic reads into a sequence, detecting variation, 
interpreting the clinical significance of specific sequence variants, and compiling a clinically 
usable report. Yet just how these methods are used in context and in what combination all 
critically impact the quality of genomically informed diagnoses. For example, many studies 
have utilized WES datasets essentially as large gene panels, interrogating data for only a 
small set of candidate genes determined based on clinical presentations [13] while others 
have developed a concept of identifying and qualifying mutations anywhere in the genome 
[9]. 
The present study was initially conceived at the 2010 Clinical Bioinformatics Summit hosted 
in Boston by Harvard University, the Children’s Hospital Informatics Program, and Harvard 
Medical School Center for Biomedical Informatics. The conference was attended by a wide 
range of stakeholders who discussed what it would take to attain a consistent and safe 
standard for clinical grade genome-wide data interpretation. One of the consensus outcomes 
of this conference was the catalytic effect that a full clinical-grade genomic diagnostic 
challenge contest would have upon the emergence of both de facto and formal standards for 
genome-scale diagnostics. 
This contest - dubbed the CLARITY Challenge (Children’s Leadership Award for the 
Reliable Interpretation and appropriate Transmission of Your genomic information) - was 
hosted by the Manton Center for Orphan Disease Research at Boston Children’s Hospital and 
the Center for Biomedical Informatics at Harvard Medical School [14]. Prizes totaling 
$25,000 were made available to the team or teams that could best analyze, interpret and 
report, in a clinically meaningful format, the results of parallel whole exome and whole 
genome sequencing (WES and WGS). The inspiration for CLARITY arose from the marked 
success of contests as a technique to focus a community on a particularly interesting and 
high-impact problem (e.g., various X Prizes). Successful competitions have accelerated 
progress in the fields of protein folding including the MATLAB Protein Folding Contest [15] 
and the International Protein Folding Competition (CASP) [16] gene identification, EGASP 
[17], and in silico tools for predicting variant pathogenicity such as the CAGI experiment 
[18]. Contests have been used to evoke ‘co-opetition’ – a collaboration centered on 
competition – in the hopes of crystallizing best practices and, thereby, accelerating the field. 
Comparative analysis is not new to this field either, as projects such as the 1000 Genomes 
Project [19] have provided the opportunity to compare technological and analytic methods 
across platforms and pipelines; its Exon Pilot project compared technologies from 454 Life 
Sciences, a Roche company (Branford, CT) Applied Biosystems (Carlsbad, CA), and 
Illumina Inc (San Diego, CA) comparing capture biases, coverage fluctuations, INDELs and 
alignment issues, population biases, and sequencing errors [20]. More recently, a prominent 
paper compared the accuracy and sensitivity of results obtained using an Illumina Hiseq 2000 
instrument and Complete Genomics’ whole genome sequencing service [21]. But there has 
not been a competition which focused on the entire front-to-back process of applying next 
generation sequencing to patient care in a manner suitable for large-scale clinical adoption. 
Admittedly, there are limitations to this method. To keep the scope of the competition 
manageable, it was focused largely on assessing the processes of variant annotation and 
subsequent medical interpretation and reporting, and no attempt was made to represent a 
range of clinical conditions and genetic models, or deal with the challenges of assessing 
clinical similarities amongst different presentations. Thus, the contest did not fully assess the 
real world challenges of finding causal mutations, but instead focused on comparative 
methods by which variants are called and assessed bioinformatically. Also outside the scope 
of the CLARITY Challenge are issues related to the importance of direct experimental 
evaluation of the functional consequence of mutation, which is a key part of interpretation of 
novel variants and where improvement is also needed. 
We present here a survey of the various methods used in the Challenge and summarize the 
opinions and attitudes of the contestants after-the-fact, regarding the practice of clinical-grade 
genome-scale diagnostics for clinical practice. 
Results and discussion 
Three families were identified by the Manton Center for Orphan Disease Research to serve as 
test cases for the CLARITY challenge, on the basis of having a child with clinical 
manifestations and/or pedigree structure suggestive of a likely genetic disease (Table 1). The 
clinical study reported here was performed under the auspices of the Boston Children’s 
Hospital Institutional Review Board (IRB) under Protocol IRB-P00000167. The organizing 
team worked closely with the IRB to define a protocol that protected the families’ interests, 
as well as the patients’ rights and prerogatives, yet allowed them to share their de-identified 
medical histories and DNA sequences with teams of qualified competitors around the world. 
  
Table 1 Clinical findings in challenge families 
Family Diagnosis Clinical history 
1 Centronuclear myopathy and bilateral 
sensorineural hearing loss 
• 10-year-old male diagnosed with centronuclear myopathy at 13 months based on clinical exam and muscle 
biopsy findings. 
• Uses a G-tube for supplemental feedings 
• Uses nighttime ventilation support 
• Able to walk limited distances (up to 4 city blocks), to run and to climb stairs with use of a railing 
• Bilateral mild low to mid-frequency hearing loss 
• No contributory family history 
2 Right sided structural heart defects and 
conduction defects 
• Multiple family members with a variety of right-sided cardiac defects ranging in severity 
• Proband is a 5-year-old female with history of a right ventricle mass which resolved spontaneously, 
persistent Right Bundle Branch Block (RBBB) and slightly dilated ascending aorta 
• Mother has the same condition, not requiring intervention 
• Maternal uncle has a pacemaker for Type II AV block and a history of pulmonary stenosis 
• Maternal aunt died in neonatal period due to cardiac defects 
• Maternal first cousin died in neonatal period due to a complex congenital cardiac defects involving 
hypertrophied right ventricle, tricuspid valve atresia, and second degree heart block 
3 Nemaline myopathy • 7-year-old male diagnosed with nemaline myopathy at 7 months based on muscle biopsy findings and 
clinical exam. 
• Bilateral club feet, requiring casting 
• Myopathic facies, decreased muscle bulk, diffuse hypotonia (axial > appendicular) decreased range of 
motion and mild finger contractures noted at 4.5 months 
• G-tube was placed at 23 months used for supplemental feedings 
• No ventilation support is needed 
• Can sit unsupported, but uses a walker to aid in ambulation 
 
DNA samples and medical records from 12 individuals in total were collected under 
informed consent. Probands and their parents (i.e., trios) were enrolled from Families 1 and 3, 
and two affected first cousins and their parents were enrolled for Family 2. WES for all 12 
participants was performed and donated by Life Technologies (Carlsbad, CA), using standard 
protocols for the LIFE Library Builder, and sequenced with ECC chemistry on SOLiD 
5500xl machines. Both raw reads (XSQ format) and aligned reads (BAM format, generated 
with LifeScope [22]) were provided. 
WGS for ten individuals (excluding an affected male cousin and his unaffected mother of the 
Family 2 proband, for whom sufficient DNA was not available) were generated and donated 
by Complete Genomics Incorporated (Mountain View, CA) utilizing their standard 
proprietary protocols and generated using their Standard Pipeline v. 2.0. VCFs, along with 
aligned reads in Complete’s proprietary format, “masterVarBeta”, were provided. 
Comprehensive clinical summaries providing clinical and diagnostic data for the presenting 
complaints and significant secondary findings were prepared by Manton Center staff from the 
primary medical records, and made available on a secure server to the contestants, together 
with the genomic data described above. 
Contestants were solicited from around the world via professional contacts, word of mouth, 
and an external website [14]. Forty teams applied to participate in the Challenge, 32 of the 
most experienced multidisciplinary groups were invited to compete, and 30 accepted the 
offer. Participants – working either independently or as teams – were tasked with working 
toward an analysis, interpretation, and report suitable for use in a clinical setting. 
At the conclusion of the Challenge, 23 teams successfully submitted entries that included 
descriptive reports of their bioinformatic analytical strategies with rationale, examples of data 
output and tables of variants, and clinical diagnostic reports for each family. Some groups 
also provided examples of their patient education materials, informed consent forms, 
preference setting documents, plans for revisable reporting, and protocols to deal with 
incidental findings. Reasons given by the seven non-completing teams for dropping out 
included technical and management issues, personnel changes within the team, inability to 
finish in time, or difficulty re-aligning the WES datasets (N = 1 each), while three teams gave 
no reason. 
The 23 completed entries represented a diverse group of approaches and treatments, with 
some groups focusing almost entirely on bioinformatic issues, others on clinical and ethical 
considerations. The most compelling entries including a detailed description of the 
bioinformatic pipelines coupled with clear, concise, and understandable clinical reports. 
Among the 23 entries, multiple genes were listed as possibly causative for all families (25 for 
family #1, 42 for family #2, and 29 for family #3). Nevertheless, a consensus was achieved 
regarding probable pathogenic variants to account for the skeletal myopathy (TTN, OMIM 
188840/603689 – reported as possibly or likely pathogenic by 8/23 groups, and recently 
published [23]), and hearing loss (GJB2, OMIM 121011/220290 – 6/23, previously 
confirmed by clinical testing) in Family 1, and the cardiac conduction defects in Family 2 
(TRPM4, OMIM 606936/604559 – reported by 13/23 groups [24]). Although no convincing 
pathogenic variants were identified for Family 3, there were two plausible candidates 
requiring further study, OBSCN and TTN, mentioned by six groups each (Table 2). 
  
Table 2 Genetic variants 
Family Phenotype Gene Genetic mutation* Protein change* Predicted effect Interpretive Status 
1 Centronuclear myopathy TTN c.[35635G > C] + [39893-1G > A] p.[V11879L] + [spl] splice/splice Likely pathogenic (res result) 
 Hearing loss GJB2 c.[101 T > C] + [35delG] p.[M34T] + [G12Vfs*2] Deleterious missense /frameshift Clinically confirmed 
2 Cardiac conduction defects TRPM4 c.503 T > A p.V168E Deleterious missense (AD) Likely pathogenic 
3 Nemaline myopathy OBSCN c.[2245G > T] + [3322 T > A] p.[G749C] + [Y1108N] missense Uncertain 
  TTN c.[84130A > T] + [14492G > A] p.[K28044X] + [C4831Y] missense/nonsense Uncertain 
*Reference sequences as follows: TTN - NM_001256850.1 and NC_000002.11, GJB2 - NM_004004.5 and NC_000013.10, TRPM4 - NM_017636.3 
and NC_000019.9, OBSCN - NM_001098623.1 and NC_000001.10.
Following the independent review and discussion by the panel of judges, one “winner”, the 
multi-institution team led by Brigham and Woman’s Hospital, Division of Genetics et al. 
(Boston) was selected, largely on the basis of having a solid pipeline that correctly identified 
most of the genes judged to be likely pathogenic, as well as for having clear and concise 
clinical reports that were judged to be best at conveying the complex genetic information in a 
clinically meaningful and understandable format. Two runners up were also cited. The first 
was a combined team from Genomatix (Munich), CeGaT (Tübingen) and the University 
Hospital of Bonn (Bonn), which had a robust pipeline that correctly identified every relevant 
gene in clear clinical reports. The second was a team from the Iowa Institute of Human 
Genetics at the University of Iowa, which had an outstanding array of patient education 
materials, procedures for patient preference setting and dealing with incidental findings, and 
policies for transfer of results of uncertain significance to an appropriate research setting if so 
desired by the patients. Content of the three winning entries is available as Additional files 1, 
2 and 3. Five additional teams were cited for “honorable mention” for having pipelines that 
identified one or more of the likely “correct” genes and for providing clear clinical reporting 
(Table 3). These 8 teams recognized by the judges are defined as “finalists” in the text and for 
purposes of statistical analysis. 
Table 3 Challenge participants 
Contest result Contestant 
Winner The Brigham and Women's Hospital, Multi-Institutional Consortium 
(Boston, MA) 
Runners-up Genomatix (Munich, Germany), CeGaT (Tübingen, Germany), Institute 
of Pathology, University Hospital of Bonn (Bonn, Germany) 
Iowa Institute of Human Genetics, University of Iowa (Iowa City, IA) 
Finalists Clinical institute of Medical Genetics, University Medical Centre 
Ljubljana (Ljubljana, Slovenia) 
Scripps Translational Science Institute (San Diego, California) 
Science For Life Laboratory (SciLifeLab), Karolinska Institute 
(Stockholm, Sweden) 
SimulConsult / Geisinger (Chestnut Hill, MA / Danville, PA) 
The Research Institute at Nationwide Children's Hospital (Columbus, 
OH) 
Completed the contest Tel Aviv University (Israel) 
Genome Institute of Singapore, A*STAR (Singapore) 
National Institutes of Health, Regeneron Pharmaceuticals and Stanford 
University (Bethesda MD, Tarrytown NY, Palo Alto CA) 
Yale School of Public Health, Division of Biostatistics (New Haven, 
CT) 
River Road Bio/SNPedia (Potomac MD) 
Pearlgen (Durham, NC) 
Institute for Systems Biology (Seattle, WA) 
Strand Life Sciences (Bangalore, India) 
Sanofi (Cambridge, MA) 
Universidad de Cantabria (Santander, Spain) 
Radboud University Nijmegen Medical Center (Nijmegen, Netherlands) 
Seven Bridges Genomics (Cambridge, MA) 
Omicia Inc/University of Utah (supported by LocusDev Inc. (now 
InVitae)) (Emeryville, CA) 
The University of Texas Health Science Center at Houston, The Brown 
Foundation Institute of Molecular Medicine (Houston, TX) 
FORGE Canada Consortium (Ottawa, Canada) 
Did not complete the contest BGI (Shenzhen, China) 
British Columbia Cancer Agency (Vancouver, Canada) 
Genedata AG (Basel, Switzerland) 
HudsonAlpha Institute for Biotechnology (Huntsville, AL) 
IRCCS Casa Sollievo della Sofferenza (San Giovanni Rotondo, Foggia, 
Italy) 
NextBio (Santa Clara, CA) 
The Medical College of Wisconsin (Milwaukee, WI) 
Criterion #1. Pipeline: What methods did each team use to 
analyze and interpret the genome sequences? 
Bioinformatic analysis 
Particulars of the bioinformatic pipelines, variant annotation and report generation 
approaches employed by the contestants are summarized in Table 4. 
Table 4 Pipeline Elements and Characteristics of successful CLARITY entries 
 Consensus (if any) Finalists Other tools used (% overall) 
Mapping    
Read Alignment Used supplied alignments 
(52%) 
Used supplied alignments 
(63%) 
Recomputed alignment data (48%) 
Variant Detection GATK and/or SAMtools (75%) GATK and/or SAMtools (75%) DNAnexus (5%). FreeBayes (5%). CGI variant table 
(5%). Avadis NGS (5%). Lifescope (5%) 
QC Metrics    
Annotation Annovar (52%) Annovar (63%) OMIM (19%), Uniprot (5%), In-house software (5%), 
SeattleSeq (5%), Variant Tools (10%), KggSeq (5%), 
SNPedia (5%), ClinVar (5%), PharmGKB (5%). 
Ingenuity (10%), SG-ADVISER (5%), HGMD (10%), 
GenomeTrax (5%), dbNSFP (5%), VEP, in house 
MapSNPs tool (5%), snpEFF (5%), Genomatix 
GeneGrid and CeGaT annotation pipeline (5%) 
Clinical extraction Sift and/or Polyphen (90%) Sift and/or Polyphen (100%) MutationTaster (10%), LRT Omega, GERP, PhyloP, and 
FreeBayes (5%) 
Validation    
Report Generation Filter by relevance to 
phenotype (71%). Consult with 
clinician in relevant area 
(63%). Clinical summary 
geared towards: (non-geneticist 
clinician (47%). Clinical 
geneticist (29%) 
Filter by relevance to 
phenotype (100%). Consult 
with clinician in relevant area 
(100%). Clinical summary 
geared towards: (non-geneticist 
clinician (38%). Clinical 
geneticist (38%) 
 
Alignment 
The majority of contestants chose to use the supplied alignments of the data. This is not 
surprising since Complete Genomics and SOLiD data require special handling of their read 
data, due to the nature of sequencing, split reads in the former, and potential for color-space 
reads in the latter. However, three teams were unable to read the data formats provided and 
did not submit complete entries. 
Alignment was recomputed for the Complete Genomics data by 5 out of 21 teams, with only 
one team reporting the aligner DNAnexus (Palo Alto, CA), while 8 out of 21 teams 
recomputed alignments for the SOLiD data. For the SOLiD data, five teams recomputed 
alignments with software aware of color-space, and two teams indicated that they compared 
their color-space results against a base-space aligner. Reported aligners used for SOLiD data 
included the LifeScope aligner, BFAST [25], BWA [26-28], Novocraft’s novoalignCS 
(Selangor, Malaysia) and the Genomatix aligner (Munich, Germany) with some teams 
utilizing multiple tools for comparison. One team performed error correction prior to 
alignment for SOLiD data using Lifescope’s SAET (SOLiD Accuracy Enhancement Tool, 
Carlsbad, CA). 
Prior to variant calling, some teams removed read duplicates using Picard [29] or SAMtools 
[30], while some teams omitted this step due to the fragment reads potentially removing non-
duplicate reads. Using whole genome and whole exome sequencing data together allowed an 
additional way to account for PCR duplication. Limited QC was performed prior to variant 
calling, with a single team using BEDtools [31] to analyze coverage QC metrics, and one 
other team reporting custom mapping QC filters. 
Variant calling 
O’Rawe et al. have suggested that choice of pipeline might be a significant source of 
variability in the outcome of NGS analyses [32]. Forty percent of teams used both Gene 
Analysis Toolkit (GATK) [33,34] and SAMtools [30] for variant calling, with the majority 
using at least one. This indicates that while there is not complete consensus, using either 
GATK, SAMtools, or both, resulted in acceptable results for the challenge. While GATK and 
SAMtools are the most popular variant callers used today and reported in this survey, their 
relative performance has been shown to vary with the sequencing depth [35,36], and direct 
comparison of variant calls resulting from parallel analysis of the same raw data by different 
variant–calling pipelines has revealed remarkably low concordance [32] leading to words of 
caution in interpreting individual genomes for genomic medicine. 
SAMtools was used by some teams to jointly call SNP and indels while recalibrating quality 
scores, while other teams used GATK to call SNPs and indels separately. Teams using 
GATK typically followed the Broad Institute’s best practice quidelines, performing indel 
realignment prior to indel calling, base quality score recalibration prior to SNP calling, and 
variant calling score recalibration (VSQR) performed after variant calling. Some teams 
ignored GATK’s base quality score recalibration mentioning that at the time GATK did not 
support SOLiD error profiles. LifeScope software containing DiBayes was also used on 
SOLiD data to call SNPs, and with local realignment to call small indels. In some cases, 
multiple variant calling methods were used and compared, with all but one using GATK, 
SAMtools, or some combination thereof. Other tools used with one mention each include: 
DNAnexus variant caller, FreeBayes [37], and Avadis NGS (v1.3.1). A number of teams 
utilized the WGS results from Complete Genomics to look for potentially pathogenic de novo 
copy number variants (CNVs), but none were found. 
A significant source of variation among the different entries was the number of de novo 
mutations reported. Less than five de novo mutations per exome, and only about 75 de novo 
mutations per genome, are expected for each trio [38,39], yet some groups reported much 
higher numbers, recognizing that many of these changes fell within areas with low or poor 
coverage. Groups that used a family-aware zygosity calling approach, such as the GATK 
module “Phase by Transmission”, developed much more refined lists of only a few potential 
de novo variants per proband, demonstrating the importance of this approach. However, 
several reported problems using the SOLiD data for this analysis as the BAM format 
provided by SOLiD was different from that expected by GATK, limiting the analysis to 
Complete Genomics data in those cases. 
Variant filtering or recalibration after initial variant calls was performed by 16 out of 20 
teams. Six teams used GATK variant quality score recalibration, with other teams reporting 
use of custom tools. Some teams used BEDtools for coverage QC metrics, but there was no 
consensus on tools to report sequencing and analysis QC metrics for post-alignment and 
variant calling. 
Teams were asked if they employed any reference datasets in calling variants or comparing 
datasets to known variants (e.g., batched variant calls, known variant lists, etc.). The most 
common reference data reported included variants from the 1000 Genomes Project, dbSNP 
[40], HapMap Project [41], NHLBI Grand Opportunity Exome Sequencing Project 
(Bethesda, MD) and the GATK Resource Bundle (distributed with GATK). Other reference 
datasets mentioned were the Mills Indel Gold Standard [42], NCBI ClinVar (Bethesda MD) 
as well as public sequencing data produced from the technologies used in this challenge. 
Coverage analysis 
One limitation of exome and genome sequencing is that the low/no coverage regions can lead 
to false positive or false negative results (sometimes 7-10% of the exons of the genes of 
interest have insufficient sequence reads to make a variant call [43]). Only 42% of teams 
quantified and reported on regions with insufficient coverage or data quality, though 50% of 
the finalists and 2 of the top 3 teams did. 
Variant validation 
Many clinical diagnostic protocols still require independent confirmation of next generation 
sequencing results, often by Sanger-based resequencing studies, to validate clinically relevant 
findings. Although that was not possible in the context of a competition where the contestants 
did not have access to DNA from the participants, 11 groups took advantage of the 
independently derived WES and WGS datasets to crosscheck and validate their findings. In 
every instance except two, the teams reported concordance between the variant calls for the 
TTN, GJB2 and TRPM4 mutations that were considered likely pathogenic. The exceptions 
were both related to calls that were considered false positive in the SOLiD data due to poor 
quality or coverage at the GJB2 and TRPM4 loci respectively. The GJB2 findings had 
previously been clinically confirmed and the contest organizers subsequently arranged for 
independent research and clinical testing which confirmed the TTN and TRPM4 variants as 
well. 
Medical interpretation of variant lists 
The most frequent methods used to annotate variants reported were Annovar [44] (52%), in-
house developed software (17%), and Ingenuity (Redwood City, CA) (12%). Other tools 
reported were Variant Tools [45], KggSeq [46], SG-ADVISER (Scripps Genome Annotation 
and Distributed Variant Interpretation Server, La Jolla, CA), Genome Trax (Wolfenbüttel, 
Germany), VAAST (Variant Annotation And Search Tool) [47], Omicia Opal [48], 
MapSNPs [49], in-house pipelines, and combinations thereof. There were a large variety of 
annotation sources (see Table 4), including but not limited to: Online Mendelian Inheritance 
in Man (OMIM) [50], Uniprot [51], SeattleSeq [52], SNPedia [53], NCBI ClinVar, 
PharmGKB [54], Human Gene Mutation Database (HGMD) [55], dbNSFP [56], and in-house 
annotations. More importantly, most teams (14/20, 70%) performed their own curation of 
annotations, for example by performing medical literature review, or for checking for error in 
externally accessed databases. Thus, manual review of annotations was deemed necessary by 
most contestants. Many teams considered family pedigree structure as an important input to 
evaluate variants as this allowed identification of potential de novo mutations, filtering for 
dominant inheritance in Family 2, ensuring Mendelian segregation and carrier status in 
parents for recessive mutations, etc. The function was largely performed manually, but use of 
automated tools such as the GATK module “Phase by Transmission” was considered by 
some groups although the underlying structure of the SOLiD data led to problems with the 
analysis. 
Reasons given for why teams did not report each of the likely pathogenic variants in Families 
1 and 2 varied by gene and by team, but in many instances, were due to decisions made 
during the medical interpretation phase of analysis. Of the 15 teams that did not report the 
TTN variants for whom survey data were available, the variant calls generated by three failed 
to identify them. 12 groups reported that their variant callers identified the two variants, but 
in six of these, automatic filters eliminated the gene from further consideration because the 
frequency of potentially pathogenic variants in this enormous gene was considered too high 
to be credible as a likely disease gene. Of the six instances where the automated pipelines 
reported the variants as potentially pathogenic, five were subsequently manually eliminated 
from further consideration because medical consultants lacked the clinical expertise or did 
not believe the published association with cardio- or skeletal-myopathy because of the high 
frequency of missense changes in the normal population. Notably, in none of the exclusions 
based on the high degree of heterogeneity of the gene was a distinction made between 
predicted truncating mutations, which are much more rare, versus more common missense 
changes. In one instance, a simple programming error prevented TTN from rising to the top of 
the candidate gene list in an automated expert system, and subsequent correction of this 
mistake resulted in a correct call of likely pathogenicity for the TTN variants in Family 1. 
Seventeen teams reported not flagging the GJB2 mutations as likely causative for hearing 
loss in the proband of Family 1. Remarkably, the variant callers employed by ten teams failed 
to identify these changes despite the fact that seven of these teams used either GATK and/or 
SAMtools. Among the remaining seven teams, two ignored the findings because they were 
considered irrelevant to the “primary phenotype” of skeletal myopathy and two reported a 
lack of clinical expertise necessary to recognize that hearing loss was a distinct phenotype. 
The remaining three teams reported that one of the previously published known pathogenic, 
variants was automatically filtered out due to its high minor allele frequency in normal 
populations. 
The TRPM4 variant in Family 2 was clinically reported by 13 of the 23 teams. Only two 
teams cited failure of their variant callers to identify this mutation, but five more reported that 
the variant was discarded due to poor quality data (low depth and noisy location with 
multiple non-reference alleles at that location in the SOLiD data) in one of more of the 
individuals that led to inconsistent calls among the different affected family members. Two 
groups failed to recognize the likely pathogenicity of this variant; one reported it as a variant 
of unknown significance while the last one’s computational genetic predictive scoring simply 
failed to weight this gene highly enough to pass the cutoff given their entered phenotypic 
parameters. The remaining group identified the TRPM4 variant, but strongly favored another 
variant in the NOS3 gene as a better explanation for the structural heart defects. 
Pathogenicity prediction of missense variants 
The most common tools to tackle the problem of determining the effect of amino acid 
substitutions on protein function for missense mutations were SIFT [57] and Polyphen [49]. 
While 80% of teams used both SIFT and Polyphen to predict pathogenicity, there was no 
significant difference in the success of the teams using both SIFT and Polyphen and those 
who used one or the other or some other tool entirely. Other tools listed by teams were 
PhyloP [58], Likelihood Ratio Test scores (LRT) [59], MutationTaster [60], GERP [61], and 
in-house developed tools. Also of note- 45% of teams attempted to assess the statistical 
confidence of assignment of pathogenicity (63% of finalists). Methods named included 
custom in-house methods (N = 3), considering gene size (N = 2), utilizing known predictions 
of pathogenicity (N = 3) and allele frequencies (N = 2), assessing commonly mutated 
segments (N = 2), and using true positive and neutral datasets within Bayesian framework (N 
= 1). 
Use of splice prediction tools is particularly important as approximately 14-15% of all 
hereditary disease alleles are annotated as splicing mutations [55]. Groups that utilized a suite 
of splice prediction tools, such as the maximum entropy model MAXENT [62], ExonScan 
[63], or positional distribution analysis [64,65], were more likely to have identified 
potentially pathogenic mutations, particularly in the TTN gene in Family 1. 
It was well recognized by all groups that allele frequency is an important consideration in 
assessing pathogenicity (though specific cutoffs were not mentioned). All groups also agreed 
that conservation of amino acid sequence across species is useful for interpretation of 
missense variants. Half of the teams (63% of finalists) took advantage of the whole genomic 
sequences to analyze non-coding variants, but none of the teams reported potential 
pathogenic changes in deep intronic or intergenic regions, even for Family 3, likely largely 
due to the undefined and uncertain status of such variants. Of teams that reported methods for 
predicting pathogenicity of non-coding variants, the most frequently used methods were 
splicing prediction algorithms (85%) and transcription factor binding site prediction (46%), 
with 23% also considering changes in known promoter/enhancer elements, and one team 
each assessing evolutionary conservation, DNAse hypersensitivity sites, and microRNA-
binding sites. 
Medical interpretation and correlation of pathogenic variants with the clinical 
presentations 
Almost all entrants performed a clinical correlation at the level of a single general diagnosis 
such as “myopathy”, “centronuclear myopathy” or “nemaline myopathy” with a list of 
predetermined candidate genes. From a clinical perspective, this reduces clinical diagnostic 
decision support to a list or panel and counts on that subset being complete for maximum 
sensitivity. However, in the case of Family 1, for example, the likely pathogenic gene was not 
generally recognized as causative for centronuclear myopathy at the time of the contest. In 
contrast, one entrant used clinically-driven diagnostic decision support [66] in which the 
clinical analysis was carried out based on a description of the patient’s various pertinent 
positive and pertinent negative findings, including their age of onset. This was then paired to 
genome analysis in a way that used a novel pertinence calculation to find the one or more 
genes among those with described phenotypes that best explains the set of pertinent positive 
and negative findings [66]. As they become refined and validated, such automated 
approaches will become a critical aid in the future for reducing the analysis times to a 
manageable level necessary to support the higher throughputs required in a clinical diagnostic 
setting. Indeed, the reported range of human hours per case required for medical 
interpretation of each case was 1–50 hours, with the automated approach requiring less than 
four hours on average to complete. 
Attitudes and remarks 
Three teams were unable to read the data formats provided and did not submit complete 
applications. This likely reflects the unique nature and format of SOLiD and Complete 
Genomics data and suggests that greater adoption of standard formats (FASTQ, SAM/BAM, 
VCF) for bioinformatics tools is required. 
We observed that finalists were significantly more likely to express a preference for 
generating their own sequencing data instead of having it generated by an external 
sequencing provider (75% vs 27%, p = 0.041). The main reason expressed for in-house data 
generation was control over the sequencing process to ensure production and assessment of 
high quality data. Other reasons expressed included cost, turnaround time, and ability for 
reanalysis. This preference may also reflect a tendency for the most experienced groups to 
have a legacy capacity to generate sequence data, and thus a bias towards using their own 
capacity. However, it also raises the reasonable possibility that integrated control of the 
process from sequence generation through variant calling is important for producing the 
highest quality variant calls. 
Overall, the teams when asked for reasons for their preference in their preferred sequencing 
technology mentioned accuracy and standardized software tools, highlighting the need for 
standard methods and tools for primary bioinformatics analysis. Furthermore, the majority of 
teams (13/18) felt that NGS should be combined with classical techniques (eg. Sanger 
sequencing, PCR methods) for confirmatory testing in clinical situations. However, a few 
recognized that with increasing depth of coverage and accuracy of alignment, NGS, 
particularly of less complex libraries such as gene panels, and possibly exomes, had potential 
to be utilized as a stand-alone test once quality control studies demonstrate sufficient 
concordance with traditional methods. 
Interestingly, all four of the finalists that did not report low-coverage or uncallable regions 
reported that they were going to begin doing so, whereas one of the non-finalists mentioned 
that they were going to add coverage quality to their reports going forward. Regions in which 
sequencing technology or reference genome specific difficulties exist are important 
considerations for accurate variant detection. Moreover, it is critical to provide locations in 
which variant calling is not possible due to lapses in coverage. 
Teams had different opinions on the level of coverage they felt was necessary for accurate 
variant calling from NGS of whole genomes. The finalists reported that they felt a higher 
level of coverage was necessary (59X average) than the rest of the teams (38X average). 
Similarly, the finalists differed for coverage required for whole exomes (74X versus 49X) or 
gene panels (121X versus 69X). 
A large majority of the teams used SIFT and Polyphen to predict the pathogenicity of a 
variant, which is a sound strategy given the programs do not always agree in protein 
predictions, and in both, specificity is reported to be high but sensitivity low [67]. 
When asked about their process to validate pathogenicity predictions, 58% of teams reported 
that they did not use any validation method, or did not have any datasets to compare 
estimates against. The finalists were more likely to have had in-house datasets to work 
against, which may be due to differences in analytical resources that could be devoted to this 
problem. Overall, this process was reported as manual for the majority of the teams. 
The diversity of approaches to preparing the contest entries made direct comparisons of 
methods difficult, so the post contest survey was designed to elicit a more homogenous 
dataset. Nevertheless, several contestants neglected to respond to some of the questions, and 
the responses to others was variable, indicating some confusion on the part of respondents 
regarding the intent of the query. 
Criterion #2. Were the methods used efficient, scalable, 
and replicable? 
There are still some manual elements to many pipelines that inhibit scalability. For an 
average case, teams reported that the interpretation process ranges from 1–50 hours (Mean 15 
± 16 hours). For the CLARITY challenge, the time spent was much greater- each case took 
from 1–200 hours (Mean 63 ± 59 hours). The average CPU time required for the analyses 
was difficult to estimate as contestants utilized different approaches, and not every entry was 
normalized for the number of parallel processors, but contestants reported utilizing 306 ± 965 
CPU hours per case (range 6–8700 hours). Reported costs to run the pipeline also varied 
considerably ranging from $100-$16,000 USD (average $3,754 ± 4,589 USD), but some 
contestants were unable to calculate salary costs leading to some lower estimates. Although 
costs have fallen dramatically, and computational resources are becoming increasingly 
available, the requirement for manual curation and interpretation of variant lists remains a 
considerable barrier to scalability that could inhibit widespread use NGS exome and genome 
diagnostics in the clinic if well-validated and substantially automated annotation tools do not 
emerge. 
Criterion #3. Was the interpretive report produced from 
genomic sequencing understandable and clinically useful? 
Consenting and return of results 
When asked about their approach to consenting and return of results in the survey, teams’ 
responses varied considerably. The question was irrelevant for a number of contestants (9/21) 
whose activities were restricted to research or contract sequencing without direct patient 
contact. Finalists were more likely to ask patients undergoing WES/WGS to sign a specific 
consent form or provide specific explanatory materials for the methodology (p = 0.057). 
Finalists were much more likely to detail how they were going to handle incidental (i.e., 
unanticipated) results (p = 0.002). However, only 35% of teams reported that their consenting 
materials include an option for patients to express their preferences around the return of 
incidental results. Most teams (76%) reported that they did not provide examples of 
consenting and/or explanatory materials for patients with their CLARITY submissions, and 
since patient interaction was not allowed for the challenge, a number of contestants simply 
considered the issue moot. However, upon reflection, many teams agreed that including 
consenting and explanatory materials would have strengthened their entries. 
Overall, it is notable that most teams’ submissions did not include specific consenting and 
explanatory materials, did not detail a predetermined approach for handling incidental results, 
and did not describe any options for patient preferences. In some cases, survey responses 
indicated that such materials and plans are used in practice, but were not included in the 
CLARITY Challenge submission because it was not clear that such content was in the scope 
of the challenge. In other cases, teams reported that they have not developed these materials 
and plans or they do not routinely focus on this aspect of the process. These findings 
highlight the fact that these components, though they are essential for the patient-facing 
implementation of clinical sequencing, are not consistently prioritized or highlighted by many 
groups involved in the clinical use of next generation sequencing. 
Reporting methods 
Reporting methods were not uniform amongst teams. Reporting the accession # for cDNA 
reference sequence was significantly more frequent in finalists versus non-finalists (87% vs 
22%, p = 0.009). However, teams did converge on some items; reporting zygosity was 
standard, with 88% of responding teams doing so. Reporting the genome build was also 
specified by 72%. That said, the genome build reporting was problematic even among the 
winning teams- two of the finalists submitted elegant reports, clearly stating the variants 
found, summarizing the location, the classification, and the parental inheritance, with a short 
interpretation (Figure 1). However, the accession numbers reported were different- a different 
build was used in each report and not specified, so it would take considerable effort to discern 
whether the two reports were truly referring to the same variants. 
Figure 1 Representative clinical report from two of the Finalist teams (A and B). 
Desirable elements include subject demographics, indication for testing, use of HUGO-
approved gene symbols, specification of the relevant variants at the gDNA, cDNA and 
protein levels including reference sequences and dbSNP identifiers, description of zygosity, 
estimation of insufficient coverage for candidate genes, and succinct clinical interpretation 
and interpretative summary. Note use of different reference sequences, and lack of 
specification in (B) makes direct correlation between reports difficult. 
Clinical reports 
Finalists were more likely to present a clinical summary report with their entry, with the trend 
approaching significance (100% vs 69%, p = 0.089). Perhaps in response to recently 
published guidelines [68], there was striking concordance in interpretation and reporting 
philosophy, with all finalist and most non-finalist teams gearing their reports towards a 
clinical geneticist/genetic counselor or non-geneticist clinician. Almost all teams agreed that 
a non-geneticist clinician should be the target audience of clinical summary reports (75% of 
finalists, 89% of non-finalists). Finalists were more likely to feel that their clinical summary 
report could be used in clinical care (100% vs 67%, p = 0.08), though there was overall 
agreement that it was important that NGS studies produce a clinical summary report that can 
be implemented in the clinic (95% ranked as “important” or “extremely important”). Most of 
the teams (80%) filtered their variant list by relevance to phenotype, with more successful 
teams more likely to do so (p = 0.074). All teams but one finalist (95%) agreed that filtering 
the variant list by relevance to phenotype is an appropriate method for communicating 
information to clinicians. 
It is still not commonplace to consult with an expert physician during report preparation, but 
doing so clearly correlated with success. Only 61% of teams routinely consult with a medical 
doctor in a relevant disease area. Finalists were significantly more likely to involve clinicians 
on a regular basis (100% vs 36%, p = 0.001). Perhaps related, in their reports prior to the 
survey, all but one of the finalists considered the hearing loss to be a separate phenotype from 
the myopathy in Family #1, while only 36% of the less successful teams did (p = 0.059). Of 
those who considered the separate phenotype, 75% of finalists and 63% of non-finalists 
considered its genetic basis. 
Conclusions 
Overall convergence and agreement across the finalists 
Overall concordance among the teams in development of variant lists was remarkable given 
the dozens of available measurement and analytical components of NGS pipelines and the 
hundreds of thousands of variants harbored by the genomes of the families. Despite the many 
paths that could be taken, the finalists utilized much the same philosophy and tools in 
processing the data and generating variant calls, and there were often minimal differences 
between finalist and non-finalist teams in the large lists of potentially pathogenic variants. A 
caveat of our study design was the choice of sequencing technologies, as Illumina platforms 
now account for a greater proportion of clinical studies than either SOLiD or Complete 
Genomics-based studies. Eight groups analyzed only the SOLiD WES data and four 
restricted their analysis to the Complete Genomics WGS data, often because of real or 
perceived difficulties with converting the eXtensible SeQuence format from the SOLiD runs 
into generic FASTQ files that would run on BWA, or unfamiliarity with the proprietary 
Complete Genomics data formats. However, as many aspects of the analytical pipelines, 
including variant calling and annotation, pathogenicity prediction, medical interpretation, and 
reporting methods, are platform independent, most results discussed here should be generally 
applicable even as sequencing technology continues to evolve. 
A number of teams preferred to recompute alignments, even though vendor alignment data 
was supplied, showing a preference for control over the analysis process and methods, and to 
ensure high quality results. Furthermore, a subset of teams expressed for the same reasons a 
preference for generating sequencing data in-house with higher coverage. 
The selection of bioinformatic tools used by the teams appeared to not differ greatly. Tools 
for variant calling centered on GATK and/or SAMtools. 80% of teams performed variant 
filtering or recalibration after initial calls were made. It is difficult to evaluate the need for 
recomputing alignment, performing indel realignment, variant filtering, or recalibration, 
given the small number of samples in this exercise. Fewer teams reported regions with 
insufficient coverage or data quality - only 42% overall. Without this information, it is 
impossible to evaluate the sensitivity of any NGS-based testing, making this an area requiring 
further development throughout the field. 
Use of reference datasets (1000 genomes, dbSNP, HapMap, NHLBI Go ESP, OMNI), and 
annotation databases (OMIM, Uniprot, SeattleSeq, SNPedia, ClinVar, PharmGKB, HGMD, 
dbNSFP, and in-house annotations) revealed considerable consensus and uniformity across 
entries. This shows the preference for a wide variety of rich data sources to maximize power 
to understand how to prioritize and contextualize variants in the presence of known 
information. Annovar was the most common annotation tool, with Ingenuity also used 
frequently. SIFT and Polyphen were overwhelmingly used to predict pathogenicity of 
missense changes. 
Supplementary analyses that were more likely to be employed by successful teams included 
consideration of allele frequency, conservation of amino acid sequence across species (for 
coding variants), use of splicing prediction algorithms and assessment of transcription factor 
binding sites (non-coding variants). Finalists were more likely to have in-house datasets to 
validate pathogenicity estimates. The use of in-house datasets to serve as validation sets for 
estimates of pathogenicity shows need for a large, publically available database for this 
purpose. 
Methods and results diverged more widely when it came to medical interpretation of the 
variant lists and correlation of variants with the clinical presentations and the medical 
literature. Nearly half of teams rate their process to determine pathogenicity as “manual,” 
while the mean time per case is over 10 hours, underscoring the need for standardized 
automated processes. Some teams have made progress towards automating this process – e.g., 
Genomatix’s automated literature search tool, LitInspector [69] was noted by judges and 
other teams alike as being best in class - and some teams mentioned a desire to utilize such 
methods in their own pipelines. SimulConsult was able to determine most variants with 
minimal manual effort and lower hours per case than average, providing a tremendous 
potential advantage in high throughput clinical environments. The ability to automate the 
genome-phenome correlations is a key capability that can make the difference between an 
analysis that can become part of clinical care and an analysis that is only practical in a 
research setting of gene discovery. 
Patient choice 
Questions of patient preference and responsibilities of laboratories to return incidental 
findings are a controversial and rapidly evolving area [70]. The team from Iowa highlighted 
the importance of patient preferences in defining the style of their reports. This represents an 
open challenge to the medical community to decide whether future reports should take into 
account patient preferences or defer to a more paternalistic model of clinically indicated 
disclosure. In terms of clinical reports and return of results, finalists were more likely to have 
consent or explanatory materials, and have a plan for incidental result return. Regardless, 
upon being surveyed, there was general agreement amongst all teams that clinical reports 
should be geared towards a clinical geneticist/genetic counselor or non-geneticist clinician. 
Variability of detection power 
The fact that only two teams identified all the likely causative mutations, despite generally 
similar approaches, demonstrates the need for consistency and rigor in approaches to variant 
interpretation. There is room for tuning the tradeoffs in sensitivity, specificity and number of 
etiologic hypotheses being tested that would benefit many teams performing NGS 
interpretation. Currently, there is little consensus on thresholds used by various teams to 
determine pathogenicity of potential disease-causing variants. In some cases contestants 
explicitly excluded variants as potentially causative due to the belief that they were likely 
sequencing or variant calling false positives or benign variants that while occurring naturally 
are not disease-causing or not solely disease-causing. Several groups, for example, noted that 
in Family 3 the proband carries multiple variants in the OBSCN gene, and that any diagnosis 
based upon variants in this gene must therefore be viewed cautiously. The titin gene, TTN, 
presented a similar dilemma as multiple potentially pathogenic variants were detected in both 
Families 1 and 3. Nevertheless, successful teams recognized the probable causative nature of 
the TTN variants in family 1 based on the fact that one was a published pathogenic change 
previously reported to cause dilated cardiomyopathy [71] and the second mutation was 
predicted to alter splicing. The winning team also cited a conference abstract, then available 
on the web [72], and now published [23], describing a parallel study of a cohort of patients 
with centronuclear myopathy with validated mutations in the TTN gene. Thus, the ability to 
correlate genomic results with emerging literature, almost in real time, provided the 
determining factor between making the correct call or not, and highlights the potential power 
of retrospectively revising reports as new research results become available: i.e., the concept 
of “revisibility.” The two GJB2 gene variants identified as causative for sensorineural hearing 
loss for the proband in Family 1 had been clinically confirmed prior to the contest, but were 
not disclosed to the participants, and therefore can serve as a validated disease causing 
variant set. Six groups identified and reported these mutations as likely responsible for the 
sensorineural hearing loss. The way teams dealt with the reported hearing loss in Family 1 is 
illustrative of variation in their understanding of the clinical phenotypes, as well as their 
views on reporting incidental findings. Two groups considered that the defect was likely part 
of the myopathic phenotype, while seven others considered the GJB2 mutations to be 
incidental, and hence did not look for or report them, because, even though the audiometry 
results were detailed in the clinical records, the hearing deficit was not listed as part of the 
primary diagnosis. 
Pre-test differential diagnosis is needed 
Fourteen of 19 teams reported having a medical geneticist on board and another included a 
physician partner, but four teams among the non-finalists did not include a medical expert on 
their teams. The fact that many teams did not appreciate the significance of GJB2 mutations 
in patient 1, suggests that additional detailed input from medical experts reviewing the 
clinical data would have been beneficial, highlighting the need to have a clinician with 
genetics expertise involved in preparing a carefully considered pre-test differential diagnosis. 
Emergence of standard of care 
Implied by the convergent methods across the leading contestants is that there is a de facto 
consensus of experts for interpretation of NGS. This represents a signal opportunity to codify 
and make this consensus explicit to ensure the greater safety and accelerated commoditization 
of NGS. Aspects that still need attention and further development to become part of the 
standard of care include robust family-aware zygosity calling, coverage estimation and 
reporting, splice site prediction and analysis, and automation of genome-phenome 
interpretation. 
While there has been rapid progress in the development and characterization of each of the 
individual components of the analysis, interpretation and reporting pipeline, there is not yet a 
set of best practices that can be applied to the entire ‘end-to-end’ process of genomic 
measurement and interpretation. Genomic medicine will require such consensus and 
standardization in order to achieve widespread, routine and reliable clinical use. While, 
eventually, organizations such as the American College of Medical Genetics and the College 
of American Pathologists will promulgate standards to be used in the management and 
accreditation of laboratories, it was the intention of the CLARITY challenge to help identify 
the emerging forerunners of such standards, and accelerate their development. The general 
feedback among contestants has been very positive and the stimulus for these groups and the 
entire industry to generate more and better tools and reports for molecular diagnosis has truly 
been achieved, also clearly documented by the number of participants. 
In summary, the contest highlighted 1) the relative uniformity of methods employed for 
alignment, variant calling, and pathogenicity prediction, 2) the need to continue developing 
publically available reference genome databases, 3) the need for more attention to coverage 
analysis and estimation of false negative rates for candidate genes, 4) the need for greater 
attention to development of clear, concise clinical reports, with common elements such as use 
of reference accession numbers and genome builds, consistent criteria for definition of 
pathogenicity (or degree of uncertainty), 5) the value of input from medical experts who 
could correlate the reported phenotypic elements with the expanding literature on genes and 
gene function, and 6) the importance of clinical genetics expertise in identifying candidate 
families for testing. Given the labor-intensive nature of variant analysis and clinical report 
generation, attention to automated genome-phenome analysis based on methods for literature 
mining and curation, as well as variant assessment, is a pressing need that will improve 
reproducibility and scalability of genomic level analyses in the future. 
Materials and methods 
Subject recruitment and informed consent 
Probands with rare medical conditions of apparent, but unknown, genetic etiology were 
identified through The Manton Center for Orphan Disease Research and their families were 
approached about participation in the contest. Every subject who provided clinical 
information and DNA specimens for analysis first provided informed consent through 
Protocol IRB-P00000167 under the supervision of the Boston Children’s Hospital IRB. 
Under the terms of this protocol, distribution of the complete genome and exome sequences 
was restricted to contest organizers and qualified contestants who all signed legal agreements 
to protect the privacy of the participants and pledges to return or destroy the sequences at the 
conclusion of the contest. Because of the risk of detection of incidental findings not related to 
the specific medical conditions identified in the clinical descriptions, and the fact that some 
participants might be publically identified through publicity related to the Challenge, the IRB 
precluded any possibility of public dissemination of the raw genomic sequences. All clinical 
and molecular datasets were de-identified prior to distribution to the contestants, and any 
identifiers included in the contest entries and Additional files are pseudonyms or codes with 
no relationships to the participants actual Protected Health Information as defined by the 
HIPAA Privacy Rule of the U.S. Department of Health and Human Services [73]. 
Contest judging 
Contest entries were evaluated by an independent group of six judges not affiliated with the 
contest organizers (I.S.K, A.H.B., and D.M.M.). Judges represented a diverse array of 
disciplines, including computer science and bioinformatics (P.N, D.M., Jr., P.S.), 
medical/human genetics (J.M., H.W.), and clinical diagnostics (E.L). Judges were asked to 
evaluate all aspects of the entries, but to pay particular attention to their areas of expertise. 
Final selection of winners was achieved by consensus among the six independent judges and 
was largely based on evaluation of three main criteria: 
1. What methods did each team use to analyze and interpret the genome sequences? 
2. Were the methods used efficient, scalable, and replicable? 
3. Was the interpretive report produced from genomic sequencing understandable and 
clinically useful? 
Although identification of the “correct” likely causative mutations for each family was 
considered, this was not an overriding factor, especially in light of the fact that the mutations 
for each family were not previously known and in some cases the results remain uncertain 
and fall into the realm of ongoing research. As it was, multiple genes were listed as possibly 
causative for all families (25 for family #1, 42 for family #2, and 29 for family #3). 
Post-contest data collection and analysis 
After the finalists and winners were declared, all teams were sent a packet including a 
structured survey of contestants’ methods and practices and copies of the winning 3 teams’ 
entries. The purpose of the survey was to provide uniformity in data for summarization and 
allow for self-assessment of each team’s entries relative to the winning entries. Of 23 groups 
that submitted contest entries, 21 (91%) returned the survey. A follow-up survey in response 
to reviewers’ suggestions resulted in 100% response rate for the 23 contestants. The complete 
set of survey questions and aggregate responses are provided as Additional file 4. Statistical 
analyses were performed using the computing environment R [74] and all reported p values 
are from unpaired t-tests. 
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